Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2023-03-27 Capital/Financing Update
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Reneo Pharmaceuticals, Inc. It registers additional shares under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The document includes legal and procedural details about the registration of securities, references to prior filings, and exhibits related to stock plans and agreements. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital/financing related filing concerning the registration of shares for employee stock plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or certification, supporting high confidence in this classification.
2023-03-27 English
10-K
Annual Report FY 2022
2023-03-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions that the company issued a press release reporting financial results for the fourth quarter and year ended December 31, 2022, and that the press release is furnished as an exhibit. The document itself does not contain the full financial statements or detailed financial analysis but rather references the press release. The length is 3814 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and states that a report or press release is furnished or attached, it should be classified as a Regulatory Filing (RNS) rather than the actual Earnings Release (ER) or Annual Report (10-K). Therefore, this document is best classified as a Regulatory Filing (RNS).
2023-03-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or other material information about the company. The content describes the achievement of target enrollment in a clinical trial and plans for future data submission, which are event updates rather than comprehensive financial reports or earnings releases. The document is about a specific event and does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-03-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content discusses the company's exposure to Silicon Valley Bank's receivership, which is a specific event disclosure. The document is relatively short (4429 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release or management discussion. It is a regulatory announcement about a specific event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-03-10 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 9, 2023. It announces the posting of an updated corporate slide presentation related to the J.P. Morgan Healthcare Conference. The document explicitly states that the presentation is furnished as an exhibit and is posted on the company's website. The text does not contain detailed financial statements or substantive financial data but rather serves as a disclosure of the availability of the investor presentation. According to the 'Menu vs Meal' rule, this is an announcement of a report (the investor presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP). The document length is under 5,000 characters, supporting that it is a brief announcement rather than a full report.
2023-01-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.